Abstract
The present clinical trial investigated the impact of selected SNPs in CES1 on the metabolic activity of the enzyme. For this purpose, we used methylphenidate (MPH) as a pharmacological probe and the d-RA/d-MPH (metabolite/parent drug) ratios as a measure of enzymatic activity. This metabolic ratio (MR) was validated against the AUC ratios (AUCd-RA /AUCd-MPH ). CES1 SNPs from 120 volunteers were identified, and 12 SNPs fulfilling predefined inclusion criteria were analysed separately, comparing the effect of each genotype on the metabolic ratios. The SNP criteria were as follows: presence of Hardy-Weinberg equilibrium, a minor allele frequency ≥ 0.01 and a clearly interpretable sequencing result in at least 30% of the individuals. Each participant ingested 10 mg of racemic methylphenidate, and blood samples were drawn prior to and 3 hours after drug administration. The SNP analysis confirmed the considerable impact of rs71647871 (G143E) in exon 4 on drug metabolism. In addition, three volunteers with markedly lower median MR, indicating decreased CES1 activity, harboured the same combination of three SNPs in intron 5. The median MR for these SNPs was 8.2 for the minor allele compared to 16.4 for the major alleles (P = 0.04). He...Continue Reading
References
Apr 15, 2004·The Journal of Pharmacology and Experimental Therapeutics·Zejin SunWilliam F Bosron
Feb 1, 2007·Pharmacogenetics and Genomics·Keiji TanimotoMasahiko Nishiyama
Aug 9, 2007·BMC Genomics·Jacob L McCauleyDouglas P Mortlock
Feb 29, 2008·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Masakiyo Hosokawa
May 20, 2008·American Journal of Human Genetics·Hao-Jie ZhuJohn S Markowitz
Sep 17, 2008·Pharmacogenetics and Genomics·Tatsuki FukamiTsuyoshi Yokoi
Mar 3, 2010·The Pharmacogenomics Journal·S YamadaA Brooks-Wilson
Jul 24, 2010·Human Genomics·David N Cooper
Jan 19, 2012·Pharmacoepidemiology and Drug Safety·Carlos TreceñoAlfonso Carvajal
May 17, 2012·Clinical Pharmacology and Therapeutics·E K TarkiainenM Niemi
Nov 1, 2012·Pharmacogenetics and Genomics·Joshua P LewisAlan R Shuldiner
Mar 8, 2013·Circulation·Guillaume ParéLars Wallentin
Mar 13, 2014·Pharmacoepidemiology and Drug Safety·Alexander M PonizovskyIsrael Fitoussi
Feb 24, 2015·Clinical Pharmacology and Therapeutics·E K TarkiainenM Niemi
Apr 29, 2015·British Journal of Clinical Pharmacology·E Katriina TarkiainenMikko Niemi
Oct 23, 2015·European Addiction Research·Elisabeth FraugerJoelle Micallef
Feb 13, 2016·Pharmacogenetics and Genomics·Jonathan C SanfordWolfgang Sadee
Nov 2, 2016·Clinical and Translational Science·Y K LyaukG Jürgens
Jan 15, 2017·British Journal of Clinical Pharmacology·Claus StageUNKNOWN INDICES Consortium
Feb 2, 2017·Pharmacogenetics and Genomics·Ditte BjerreUNKNOWN INDICES Consortium
Apr 25, 2017·PloS One·Jaeseong OhKyoung Soo Lim
Aug 9, 2017·Pharmacogenomics·Laura Ferrero-MilianiHenrik Berg Rasmussen
Feb 20, 2018·Pharmacogenomics·Ditte BjerreThe Indices Consortium
Jun 23, 2018·Basic & Clinical Pharmacology & Toxicology·Pernille Tveden-NyborgJens Lykkesfeldt